# Vancomycin and Lipoglycopeptides

## Introduction

### Evolution of Glycopeptide Therapy

Vancomycin was introduced into clinical practice in 1958 and initially earned the unflattering nickname "Mississippi Mud" owing to the significant impurities present in early formulations. Modern vancomycin preparations are highly purified, and the drug has endured as the backbone of empiric gram-positive coverage in hospitalized patients for nearly seven decades. Despite the emergence of numerous alternatives, vancomycin remains the default agent for empiric MRSA coverage in most clinical settings, a position that reflects both its established efficacy and the cumulative clinical experience informing its use.

The development of newer lipoglycopeptides, including dalbavancin, oritavancin, and telavancin, has expanded the therapeutic armamentarium by offering unique pharmacokinetic advantages and distinct clinical niches. Each of these agents modifies the basic glycopeptide scaffold with lipophilic side chains that enhance membrane binding, prolong the half-life, and in some cases confer activity against vancomycin-resistant organisms.

The 2020 IDSA/ASHP/SIDP vancomycin consensus guidelines fundamentally changed the approach to vancomycin monitoring by establishing AUC-guided dosing as the standard and relegating trough-only monitoring to the status of an outdated practice associated with unnecessary toxicity. This paradigm shift represents one of the most impactful guideline changes in recent infectious disease practice.

## Vancomycin - Mechanism of Action

### Molecular Target

Vancomycin binds to the D-alanyl-D-alanine terminus of peptidoglycan precursors, specifically the lipid II intermediate, through a network of five hydrogen bonds. This binding prevents both transglycosylation (the polymerization of disaccharide-pentapeptide units into glycan chains) and transpeptidation (the cross-linking of peptide side chains), thereby disrupting cell wall synthesis at two distinct steps. This dual mechanism distinguishes vancomycin from beta-lactams, which inhibit only transpeptidation.

Vancomycin is bactericidal against most gram-positive organisms but exhibits only bacteriostatic activity against enterococci, a limitation that necessitates the use of synergistic combination therapy for serious enterococcal infections such as endocarditis. The large molecular weight of vancomycin, approximately 1450 daltons, prevents its passage through the outer membrane of gram-negative organisms, rendering all gram-negatives inherently resistant.

### Spectrum of Activity

The clinical spectrum of vancomycin encompasses MRSA, MSSA (though it is inferior to beta-lactams for MSSA), coagulase-negative staphylococci, all streptococcal species, Enterococcus faecalis (bacteriostatic), Enterococcus faecium (when VanA and VanB negative), Clostridioides difficile (oral formulation only, as vancomycin is not absorbed systemically), Corynebacterium species, Listeria monocytogenes (bacteriostatic), and Bacillus species. Vancomycin is not active against gram-negative organisms, VRE expressing VanA or VanB phenotypes, or some coagulase-negative staphylococcal isolates exhibiting MIC creep.

## Vancomycin Pharmacokinetics and Dosing

### Standard Dosing

For serious infections, vancomycin therapy should be initiated with a loading dose of 25 to 30 mg/kg based on actual body weight, rounded to the nearest 250 mg. This loading dose ensures rapid achievement of therapeutic concentrations in the critical early hours of treatment. Maintenance dosing is typically 15 to 20 mg/kg actual body weight administered every 8 to 12 hours, with interval adjustments based on renal function. For a typical 70-kilogram patient with normal renal function, this translates to 1000 to 1500 mg every 12 hours.

Oral vancomycin dosing for Clostridioides difficile infection follows entirely different principles, as the drug is not absorbed systemically and achieves its therapeutic effect through direct intraluminal activity. The standard oral dose for non-severe CDI is 125 mg four times daily, while severe or fulminant CDI is treated with 500 mg four times daily.

### AUC-Guided Dosing (2020 Consensus Guidelines)

The 2020 consensus guidelines established an AUC/MIC target of 400 to 600, assuming an MIC of 1 mg/L as determined by broth microdilution. This target represents a fundamental shift from the prior approach of targeting trough concentrations of 15 to 20 mcg/mL. The rationale for this change is compelling: trough-guided dosing at the higher end of the traditional target range correlates with AUC values of approximately 600 to 800, which exceeds the therapeutic target and is associated with significantly higher rates of acute kidney injury without providing additional antimicrobial benefit.

Two methods are recommended for AUC estimation. The first employs first-order pharmacokinetic equations using two drug levels: a peak obtained 1 to 2 hours after the end of infusion and a trough obtained before the next dose, both at steady state. The second and preferred method utilizes Bayesian estimation software, which incorporates population pharmacokinetic models to estimate the AUC from as few as a single drug level, dramatically simplifying the clinical workflow while maintaining accuracy.

### Pharmacokinetic Considerations

Vancomycin exhibits a volume of distribution of 0.4 to 1.0 L/kg, which increases substantially in fluid overload, sepsis, and burns. Protein binding is approximately 50 to 55 percent, primarily to albumin. Elimination is 80 to 90 percent renal via glomerular filtration, with a half-life of 4 to 6 hours in patients with normal renal function that extends to 7 to 10 days in anuric patients. In patients receiving intermittent hemodialysis, vancomycin should be dosed post-dialysis, as high-flux membranes remove 25 to 40 percent of the drug per session. For patients on continuous renal replacement therapy, a loading dose of 15 to 25 mg/kg is followed by maintenance dosing of 7.5 to 10 mg/kg every 12 hours, with adjustment guided by drug level monitoring.

<image>A step-by-step clinical workflow diagram for vancomycin AUC-guided dosing. Step 1: "Calculate loading dose (25-30 mg/kg ABW)" with a calculator icon. Step 2: "Start maintenance dosing (15-20 mg/kg q8-12h based on CrCl)." Step 3: "Obtain steady-state levels -- Option A: Two levels (trough before 4th dose + peak 1-2h post-infusion) or Option B: Single trough level with Bayesian software." Step 4: "Calculate AUC using first-order PK equations or Bayesian estimation." Step 5: "Adjust dose to achieve AUC/MIC 400-600 (assuming MIC=1)." Include a decision branch: "AUC <400: increase dose 20-25%" and "AUC >600: decrease dose 20-25%." Use a clean vertical flowchart with blue and green color scheme.</image>

## Vancomycin Adverse Effects

### Nephrotoxicity

Vancomycin-associated nephrotoxicity occurs in 5 to 25 percent of treated patients, depending on the definition used and the presence of concomitant nephrotoxins. The mechanism involves oxidative stress-mediated proximal tubular injury. Risk factors include AUC values exceeding 600, concomitant administration of piperacillin-tazobactam (a signal that persists despite ongoing debate about its clinical significance), aminoglycoside co-administration, vasopressor use, and the ICU setting.

The question of vancomycin plus piperacillin-tazobactam nephrotoxicity has been addressed by the ACORN trial, published in 2024, which was a randomized trial comparing empiric piperacillin-tazobactam versus cefepime. The trial found a higher rate of acute kidney injury with piperacillin-tazobactam (9.9 percent versus 8.1 percent), though debate continues regarding the clinical significance and mechanism of this finding. The transition to AUC-guided dosing has been shown to reduce nephrotoxicity rates compared with trough-guided dosing, providing yet another argument for the adoption of modern monitoring practices.

### Infusion-Related Reactions (Red Man Syndrome)

Red man syndrome is a non-IgE-mediated histamine release reaction triggered by rapid vancomycin infusion. It manifests as flushing, erythema, and pruritus of the upper body and face, with rare progression to hypotension. Prevention involves infusing vancomycin over at least 1 hour, extending to at least 2 hours for doses exceeding 1.5 grams, and pretreating with antihistamines for patients who have experienced recurrent reactions. It is essential to communicate to patients and clinical teams that red man syndrome is not a true allergy and does not preclude future vancomycin use.

### Other Adverse Effects

Ototoxicity is rare and typically associated with very high trough levels exceeding 30 mcg/mL or concomitant aminoglycoside therapy. Neutropenia occurs in patients receiving vancomycin for longer than 14 days and is reversible upon discontinuation; weekly complete blood count monitoring is advisable for prolonged courses. Linear IgA bullous dermatosis is a rare autoimmune blistering disorder associated with vancomycin, and DRESS syndrome, though rare, is a recognized vancomycin-associated adverse reaction.

## Vancomycin Resistance

### Mechanism in Enterococci (VRE)

Vancomycin resistance in enterococci is mediated by gene clusters that modify the peptidoglycan target from D-Ala-D-Ala to D-Ala-D-Lac, reducing vancomycin binding affinity by approximately 1000-fold. The VanA phenotype confers high-level resistance with MICs of 64 mg/L or greater, is plasmid-mediated and inducible, and produces resistance to both vancomycin and teicoplanin. VanA is the most common resistance genotype in E. faecium.

The VanB phenotype produces moderate-level resistance with MICs ranging from 4 to 1000 mg/L. Organisms expressing VanB are resistant to vancomycin but remain susceptible to teicoplanin. VanB is chromosomally encoded and inducible. The VanC genotype is intrinsic to E. gallinarum and E. casseliflavus and produces low-level resistance through the synthesis of D-Ala-D-Ser in place of D-Ala-D-Ala. VanC-mediated resistance is of limited clinical significance, with MICs typically in the range of 2 to 32 mg/L.

| Phenotype | Target Modification | MIC Range (mg/L) | Vancomycin | Teicoplanin | Genetic Basis | Location |
|---|---|---|---|---|---|---|
| VanA | D-Ala-D-Lac | ≥64 | Resistant | Resistant | Plasmid-mediated, inducible | E. faecium (most common) |
| VanB | D-Ala-D-Lac | 4-1000 | Resistant | Susceptible | Chromosomal, inducible | E. faecalis, E. faecium |
| VanC | D-Ala-D-Ser | 2-32 | Low-level resistant | Susceptible | Intrinsic, constitutive | E. gallinarum, E. casseliflavus |

### MIC Creep and Heteroresistance in Staphylococci

Vancomycin-intermediate S. aureus (VISA) is defined by MICs of 4 to 8 mg/L and arises through thickening of the cell wall, which traps vancomycin molecules in the outer layers and prevents them from reaching their peptidoglycan targets at the cytoplasmic membrane. Heterogeneous VISA (hVISA) refers to isolates that test within the susceptible MIC range by standard methods but harbor subpopulations with intermediate-level resistance, a phenomenon with a prevalence estimated at 1 to 5 percent.

Vancomycin-resistant S. aureus (VRSA), with MICs of 16 mg/L or greater, arises through the acquisition of the vanA operon from VRE and is exceedingly rare, with fewer than 20 confirmed cases in the United States. Of more immediate clinical concern is the observation that vancomycin MICs of 2 mg/L, while technically within the susceptible range by CLSI criteria, are associated with higher rates of treatment failure. When the MIC reaches this level, alternative agents should be strongly considered.

## Lipoglycopeptides

### Dalbavancin

Dalbavancin is a semi-synthetic lipoglycopeptide distinguished by an extraordinarily long half-life of approximately 14.4 days, which permits single-dose or two-dose treatment of infections that would otherwise require weeks of daily intravenous therapy. The approved dosing for acute bacterial skin and skin structure infections is either a single 1500 mg intravenous dose or 1000 mg on day 1 followed by 500 mg on day 8.

While its FDA-approved indication is limited to ABSSSI, the clinical applications of dalbavancin are expanding rapidly. Off-label uses include osteomyelitis, prosthetic joint infections, endocarditis (as explored in the DALBUSE study), and simplification of outpatient parenteral antibiotic therapy. Its spectrum covers MRSA, MSSA, and streptococci but does not include VanA VRE, though some activity against VanB strains has been observed. The ability to deliver complete antimicrobial therapy in a single dose offers transformative advantages for patients with adherence challenges, difficulty obtaining or maintaining intravenous access, or those for whom daily OPAT infusions represent an undue burden.

### Oritavancin

Oritavancin is a semi-synthetic lipoglycopeptide with a unique triple mechanism of action: it inhibits transglycosylation, inhibits transpeptidation, and directly disrupts bacterial membrane integrity through insertion of its lipophilic tail into the lipid bilayer. This membrane-disruptive activity is bactericidal against enterococci and, most importantly, bypasses the D-Ala-D-Lac modification that confers VanA resistance. Oritavancin is therefore active against both VanA and VanB VRE, making it the only lipoglycopeptide with this capability.

Oritavancin has a half-life of approximately 10 days and is administered as a single 1200 mg intravenous dose over 3 hours for ABSSSI. A critical practical consideration is that oritavancin interferes with phospholipid-dependent coagulation assays, causing factitious prolongation of the aPTT for up to 120 hours after administration. This interaction necessitates caution in patients requiring serial aPTT monitoring, such as those receiving unfractionated heparin.

### Telavancin

| Feature | Vancomycin | Dalbavancin | Oritavancin | Telavancin |
|---|---|---|---|---|
| Half-life | 4-6 hours | ~14.4 days | ~10 days | 8 hours |
| Dosing | 15-20 mg/kg q8-12h | 1500 mg x1 or 1000 mg + 500 mg day 8 | 1200 mg x1 | 10 mg/kg q24h |
| FDA Indication | Multiple | ABSSSI | ABSSSI | cSSSI, HAP/VAP |
| VanA VRE Activity | No | No | Yes | No |
| VanB VRE Activity | No | Some | Yes | No |
| Membrane Disruption | No | No | Yes | Yes |
| Key Concern | Nephrotoxicity, AUC monitoring | Off-label use expanding | Interferes with aPTT (up to 120h) | Nephrotoxicity (CrCl must be >50) |

Telavancin is a semi-synthetic lipoglycopeptide with a dual mechanism involving D-Ala-D-Ala binding and membrane depolarization. It is dosed at 10 mg/kg intravenously every 24 hours and carries FDA approval for complicated skin and skin structure infections and for hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible gram-positives. A significant nephrotoxicity signal limits its use, with creatinine clearance required to be above 50 mL/min and the drug contraindicated at clearances below 30. Its role in clinical practice is primarily reserved for situations in which other agents have failed or cannot be used.

<image>A comparison table infographic of the three lipoglycopeptides (dalbavancin, oritavancin, telavancin) alongside vancomycin. Columns should include: drug name, mechanism of action, half-life, dosing regimen, FDA indications, VRE activity (VanA/VanB), key adverse effects, and special considerations. Use green highlighting for advantages and red for disadvantages/warnings. Include molecular structure silhouettes next to each drug name showing the lipophilic side chain that distinguishes lipoglycopeptides from vancomycin. Use a clean medical reference table format.</image>

## Clinical Decision-Making: When to Use What

### Vancomycin vs. Alternatives for MRSA

Vancomycin remains the first-line agent for MRSA bacteremia and endocarditis according to current IDSA guidelines. However, several clinical scenarios warrant consideration of alternative agents. When the vancomycin MIC reaches 2 mg/L by broth microdilution, treatment failure rates increase appreciably, and daptomycin should be substituted for bacteremia. Persistent bacteremia extending beyond 3 to 5 days on appropriate vancomycin therapy should prompt switching to daptomycin, with or without the addition of ceftaroline or TMP-SMX as synergistic partners. Significant nephrotoxicity or the inability to achieve the target AUC, as well as a history of prior VISA or hVISA infection, are additional indications for alternative therapy.

A critical principle that merits constant emphasis is the inferiority of vancomycin compared to nafcillin or cefazolin for MSSA infections. Vancomycin demonstrates slower bactericidal activity and higher failure rates in MSSA bacteremia. De-escalation from vancomycin to an anti-staphylococcal beta-lactam must occur immediately upon confirmation of methicillin susceptibility, without exception.

### Role of Lipoglycopeptides

The lipoglycopeptides occupy growing clinical niches. Dalbavancin and oritavancin are particularly valuable for ABSSSI management in patients who cannot complete oral therapy, require directly observed treatment, or would benefit from outpatient management without the need for PICC-line placement and daily infusions. Emerging data support dalbavancin's efficacy in bone and joint infections, where its ultra-long half-life facilitates early hospital discharge while maintaining weeks of therapeutic drug exposure. Oritavancin's unique activity against VanA VRE provides a therapeutic option for VRE infections when linezolid and daptomycin are not tolerated or have failed.

<image>A clinical decision algorithm for selecting glycopeptide/lipoglycopeptide therapy. Start with "Gram-positive infection requiring IV therapy." First branch: "MRSA vs. MSSA" -- MSSA goes to "Nafcillin/Cefazolin (preferred)" with a note "Vancomycin inferior for MSSA." MRSA branch leads to "Severity assessment." Severe (bacteremia, endocarditis, pneumonia) leads to "Vancomycin AUC-guided dosing (first-line)" with branches for "Treatment failure/MIC≥2" leading to "Daptomycin +/- ceftaroline." Moderate (ABSSSI, uncomplicated) leads to decision between "Standard vancomycin," "Dalbavancin single-dose," or "Oritavancin single-dose" based on patient factors (adherence, IV access, outpatient). Include a VRE pathway leading to "Oritavancin, linezolid, or daptomycin." Use a professional medical decision tree format.</image>

## Key Clinical Pearls

- AUC/MIC 400-600 is the current vancomycin dosing target; trough-only monitoring is associated with unnecessary nephrotoxicity and should be abandoned
- Vancomycin is inferior to beta-lactams for MSSA -- always de-escalate when susceptibilities return
- When vancomycin MIC is 2 mg/L (susceptible by CLSI but "intermediate" territory), treatment failure rates increase; consider daptomycin for bacteremia
- Dalbavancin's ultra-long half-life allows single-dose ABSSSI treatment and is transforming outpatient ID practice
- Oritavancin is the only lipoglycopeptide with activity against VanA VRE -- unique membrane-disrupting mechanism
- Red man syndrome is NOT an allergy; slow infusion and antihistamine premedication allow safe re-administration
- The vancomycin + piperacillin-tazobactam AKI signal remains clinically relevant -- consider cefepime or meropenem when combination needed

## References
1. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious MRSA infections: a revised consensus guideline and review. *Am J Health Syst Pharm*. 2020;77(11):835-864.
2. Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. *Clin Infect Dis*. 2011;52(1):31-40.
3. Dunne MW, Puttagunta S, Sprenger CR, et al. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. *Antimicrob Agents Chemother*. 2015;59(4):1849-1855.
4. Luther MK, Mermel LA, Gao P, et al. Clinical and economic outcomes of vancomycin plus piperacillin-tazobactam versus alternative antibiotic combinations. *Pharmacotherapy*. 2024.
5. Courvalin P. Vancomycin resistance in gram-positive cocci. *Clin Infect Dis*. 2006;42(Suppl 1):S25-S34.